Inclusion Criteria:  histologically or cytologically diagnosed non-squamous NSCLC of stage IIIB or IV (based on the 7th edition of the TNM classification) or recurrent; an EGFR mutation, including an exon-19 deletion (Ex19del), L858R, or other (L861Q, G719A, G719C, or G719S), as well as the T790M mutation of EGFR as detected in a tissue or liquid biopsy sample obtained after disease progression during first-line EGFR-TKI (gefitinib, erlotinib, or afatinib) treatment; WHO performance status of 0 or 1; no prior neoadjuvant or adjuvant chemotherapy in the 12 months preceding study enrollment; adequate bone marrow reserve and organ function.  Exclusion Criteria:  treatment with an EGFR-TKI within 7 days of the first dose of the study treatment; symptomatic CNS metastases; evidence of interstitial pneumonia, pulmonary fibrosis, or radiation pneumonitis requiring steroid treatment as revealed by a computed tomography (CT) scan.